Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety, efficacy, and pharmacokinetics of OPC-67683 (delamanid) in patients with pulmonary tuberculosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• OPC-67683 (delamanid)

Snippet

Sponsor: Otsuka Frankfurt Research Institute GmbH | Conditions: Pulmonary Tuberculosis | Phase 2 | Status: COMPLETED